Doonan, J. et al. (2018) Failure of the anti-inflammatory parasitic worm product ES-62 to provide protection in mouse models of type I diabetes, multiple sclerosis, and inflammatory bowel disease. Molecules, 23(10), 2669. (doi: 10.3390/molecules23102669) (PMID:30336585) (PMCID:PMC6222842)

Ball, D., Al-Riyami, L., Harnett, W. and Harnett, M. (2018) IL-33/ST2 signalling and crosstalk with FcεRI and TLR4 is targeted by the parasitic worm product, ES-62. Scientific Reports, 8, 4497. (doi: 10.1038/s41598-018-22716-9) (PMID:29540770) (PMCID:PMC5852134)

Suckling, C. J., Alam, S., Olson, M. A., Saikh, K. U., Harnett, M. M. and Harnett, W. (2018) Small Molecule Analogues of the parasitic worm product ES-62 interact with the TIR domain of MyD88 to inhibit pro-inflammatory signalling. Scientific Reports, 8, 2123. (doi: 10.1038/s41598-018-20388-z) (PMID:29391452) (PMCID:PMC5794923)

Lumb, F. E., Doonan, J., Bell, K. S., Pineda, M. A. , Corbet, M., Suckling, C. J., Harnett, M. M. and Harnett, W. (2017) Dendritic cells provide a therapeutic target for synthetic small molecule analogues of the parasitic worm product, ES-62. Scientific Reports, 7, 1704. (doi: 10.1038/s41598-017-01651-1) (PMID:28490801) (PMCID:PMC5431997)

Eason, R. J., Bell, K. S., Marshall, F. A., Rodgers, D. T., Pineda, M. , Steiger, C. N., Al-Riyami, L., Harnett, W. and Harnett, M. M. (2016) The helminth product, ES-62 modulates dendritic cell responses by inducing the selective autophagolysosmal degradation of TLR-transducers, as exemplified by PKCδ. Scientific Reports, 6, 37276. (doi: 10.1038/srep37276) (PMID:27869138) (PMCID:PMC5116678)

Janicova, L., Rzepecka, J., Rodgers, D.T., Doonan, J., Bell, K.S., Lumb, F.E., Suckling, C.J., Harnett, M.M. and Harnett, W. (2016) Testing small molecule analogues of theAcanthocheilonema viteaeimmunomodulator ES-62 against clinically relevant allergens. Parasite Immunology, 38(6), pp. 340-351. (doi: 10.1111/pim.12322) (PMID:27059010) (PMCID:PMC4913752)

Coltherd, J. C., Rodgers, D. T., Lawrie, R. E., Al-Riyami, L., Suckling, C. J., Harnett, W. and Harnett, M. M. (2016) The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma. Scientific Reports, 6, 19224. (doi: 10.1038/srep19224) (PMID:26763929) (PMCID:PMC4725896)

Rodgers, D. T., Pineda, M. A. , Suckling, C. J., Harnett, W. and Harnett, M. M. (2015) Drug-like analogues of the parasitic worm-derived immunomodulator ES-62 are therapeutic in the MRL/Lpr model of systemic lupus erythematosus. Lupus, 24(13), pp. 1437-1442. (doi: 10.1177/0961203315591031) (PMID:26085597) (PMCID:PMC4616909)

Al-Riyami, L., Rodgers, D. T., Rzepecka, J., Pineda, M. A. , Suckling, C. J., Harnett, M. M. and Harnett, W. (2015) Protective effect of small molecule analogues of the Acanthocheilonema viteae secreted product ES-62 on oxazolone-induced ear inflammation. Experimental Parasitology, 158, pp. 18-22. (doi: 10.1016/j.exppara.2015.03.025) (PMID:25836375) (PMCID:PMC4659540)

Bell, K. S., Al-Riyami, L., Lumb, F. E., Britton, G. J., Poole, A. W., Williams, C. M., Braun, U., Leitges, M., Harnett, M. and Harnett, W. (2015) The role of individual protein kinase C isoforms in mouse mast cell function and their targeting by the immunomodulatory parasitic worm product, ES-62. Immunology Letters, 168(1), pp. 31-40. (doi: 10.1016/j.imlet.2015.09.001) (PMID:26343793) (PMCID:PMC464348)

Rzepecka, J. et al. (2015) Prophylactic and therapeutic treatment with a synthetic analogue of a parasitic worm product prevents experimental arthritis and inhibits IL-1β production via NRF2-mediated counter-regulation of the inflammasome. Journal of Autoimmunity, 60, pp. 59-73. (doi: 10.1016/j.jaut.2015.04.005) (PMID:25975491) (PMCID:PMC4459730)

Rodgers, D. T., McGrath, M. A., Pineda, M. A. , Al-Riyami, L., Rzepecka, J., Lumb, F., Harnett, W. and Harnett, M. M. (2015) The parasitic worm product, ES-62 targets MyD88-dependent effector mechanisms to suppress ANA production and proteinuria in MRL/Lpr mice. Arthritis and Rheumatology, 67(4), pp. 1023-1035. (doi: 10.1002/art.39004) (PMID:25546822) (PMCID:PMC4409857)

Pineda, M.A. , Eason, R.J., Harnett, M.M. and Harnett, W. (2015) From the worm to the pill, the parasitic worm product ES-62 raises new horizons in the treatment of rheumatoid arthritis. Lupus, 24(4-5), pp. 400-411. (doi: 10.1177/0961203314560004) (PMID:25801883)

Aprahamian, T. R., Zhong, X., Amir, S., Binder, C. J., Chiang, L.-K., Al-Riyami, L., Gharakhanian, R., Harnett, M. M. , Harnett, W. and Rifkin, I. R. (2015) The immunomodulatory parasitic worm product ES-62 reduces lupus-associated accelerated atherosclerosis in a mouse model. International Journal for Parasitology, 45(4), pp. 203-207. (doi: 10.1016/j.ijpara.2014.12.006) (PMID:25666929) (PMCID:PMC4355381)

Pineda, M. A. , Al-Riyami, L., Harnett, W. and Harnett, M. M. (2014) Lessons from helminth infections: ES-62 highlights new interventional approaches in rheumatoid arthritis. Clinical and Experimental Immunology, 177(1), pp. 13-23. (doi: 10.1111/cei.12252) (PMID:24666108) (PMCID:PMC4089150)

Pineda, M. A. , Rodgers, D. T., Al-Riyami, L., Harnett, W. and Harnett, M. M. (2014) ES-62 protects against collagen-induced arthritis by resetting IL-22 towards resolution of inflammation in the joints. Arthritis and Rheumatology, 66(6), pp. 1492-1503. (doi: 10.1002/art.38392) (PMID:24497523)

Harnett, M. , Harnett, W. and Pineda, M. A. (2014) The parasitic worm product ES-62 up-regulates IL-22 production by γδ T cells in the murine model of Collagen-Induced Arthritis. Inflammation and Cell Signaling, 1(5), e308. (doi: 10.14800/ics.308)

Pineda, M.A. , McGrath, M.A., Smith, P.C., Al-Riyami, L., Rzepecka, J., Gracie, J.A., Harnett, W. and Harnett, M.M. (2012) The parasitic helminth product ES-62 suppresses pathogenesis in collagen-induced arthritis by targeting the interleukin-17–producing cellular network at multiple sites. Arthritis and Rheumatism, 64(10), pp. 3168-3178. (doi: 10.1002/art.34581) (PMID:22729944)